Increased emergency room visits or hospital admissions in females after 12-month MMR vaccination, but no difference after vaccinations given at a younger age  by Wilson, Kumanan et al.
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Background:  Previous  studies  have  suggested  that  a child’s  sex  may  be a  predictor  of  vaccine  reactions.
Methods:  We  used  a self-controlled  case  series  design,  an  extension  of retrospective  cohort  methodology
which  controls  for ﬁxed  confounders  using  a conditional  Poisson  modeling  approach.  We  compared  a
risk  period  immediately  following  vaccination  to  a control  period  farther  removed  from  vaccination  in
each  child  and  estimated  the  relative  incidence  of  emergency  room  visits  and/or  hospital  admissions
following  the 2-, 4-,  6-,  and  12-month  vaccinations  to  investigate  the effect  of sex on  relative  incidence.
All  infants  born  in  Ontario,  Canada  between  April  1, 2002  and  March  31, 2009  were  eligible  for  study
inclusion.
Results:  In  analyses  combining  immunizations  at 2, 4  and  6 months  and  examining  these  vaccinations
separately,  there  was  no  signiﬁcant  relationship  between  the relative  incidence  of an  event  and  sex
of  the  child.  At 12  months,  we  observed  a signiﬁcant  effect  of sex,  with  female  sex  being  associated
with  a  signiﬁcantly  higher  relative  incidence  of events  (P =  0.0027).  The relative  incidence  ratio  (95%  CI)
comparing  females  to  males  following  the  12-month  vaccination  was  1.08  (1.03  to 1.14), which  translates
to  192  excess  events  per  100,000  females  vaccinated  compared  to the  number  of events  that  would  have
occurred  in 100,000  males  vaccinated.
Conclusions:  As  the  MMR  vaccine  is given  at 12  months  of age  in  Ontario,  our  ﬁndings  suggest  that  girls  may
have  an  increased  reactogenicity  to  the  MMR  vaccine  which  may  be  indicative  of general  sex  differences
in  the  responses  to the measles  virus.
 201©
. IntroductionWhile pediatric vaccinations have been clearly demonstrated
o be safe and effective, mild reactions can occur in the process of
reating immunity that may  result in health care services utiliza-
ion. Identifying children at increased risk of these events following
accination is important for the purpose of communicating risk to
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parents and also for providing insight into the pathophysiology of
these events. Previous studies have shown that a child’s sex may  be
an important predictor of vaccine reactions, with females being at
increased risk of adverse events, particularly in the cases of young
women who  received rubella vaccination [1] and in infant girls who
received the now discontinued high titer measles vaccines [2–6].
We have previously demonstrated that aggregate health ser-
vices utilization serves as a useful surrogate for reactions following
vaccination [7,8]. Using the self-controlled case series design and
graphical representation of events before and after vaccination we
have identiﬁed a marked reduction in events before all pediatric
vaccinations consistent with the healthy vaccinee effect [9,10]. We
Open access under CC BY-NC-ND license.observed no increase in events following administration of the non-
living vaccines at 2, 4 and 6 months of age during the ﬁrst 3 days
following vaccination, the expected at risk period [9]. However,
any effect may  have been obscured by the healthy vaccinee effect
cense.
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nd when we examined the more reactogenic whole cell pertussis
accine, an elevation in events was evident in the ﬁrst 24 h [8]. We
ave also identiﬁed a signiﬁcant elevation in incidence of hospi-
al admissions or emergency room visits from days 4 to 12 post
2-month (MMR)  vaccination compared to a control period (Rela-
ive Incidence (95% CI) = 1.33 (1.29 to 1.38) [10]. This risk period is
onsistent with the biologically expected period and previous stud-
es and our estimate of febrile seizures was also consistent with
revious estimates [11–14].
Using our existing analytic infrastructure, we sought to examine
he association between sex and health services utilization follow-
ng standard pediatric immunizations, deﬁned as emergency room
ER) visits or hospitalizations, during a pre-speciﬁed ‘at risk’ period
fter vaccination.
. Methods
We  conducted this study using VISION (Vaccine and Immuniza-
ion Surveillance in Ontario), an analysis infrastructure that was
reated using linked health administrative data to monitor vac-
ine safety and efﬁcacy in Ontario [7]. Using this infrastructure,
e examined the effect of sex on rates of ER visits and/or hospi-
al admissions within pre-deﬁned risk periods following standard
ediatric immunizations administered at 2, 4, 6 and 12 months
n infants born between April 1st, 2002 and March 31, 2009. In
ntario, Canada, standard pediatric vaccines administered at 2, 4
nd 6 months of age during our study period included those against
iphtheria, pertussis, tetanus, polio, haemophilus inﬂuenzae type b
Hib) as one vaccination, and pneumococcus as a separate vaccina-
ion. Recommended immunizations at 12 months of age consisted
f a vaccine against measles, mumps  and rubella (MMR  vaccine)
hroughout the entire study period and in addition, as of September
004, a vaccine against meningococcal disease (type C) was  added
o the schedule of recommended vaccinations at 12 months of age.
Our study included all children born in Ontario between April
st, 2002 and March 31st, 2009, who were present in the Insti-
ute for Clinical Evaluative Sciences’ Registered Persons Database.
e ascertained vaccination events for our study cohort at 2, 4, 6
nd 12 months of age using general billing codes for vaccination
n the Ontario Health Insurance Plan Database, including vaccines
dministered on the exact due dates, as well as those which were
dministered up to 14 days before or 40 days after the due dates. We
dentiﬁed hospital admissions for our study cohort using the Cana-
ian Institute for Health Information’s Discharge Abstract Database
nd ER visits using the National Ambulatory Care Registration Sys-
em. We  assessed the relative severity of ER visits by comparing
he mean Canadian Triage and Acuity Scale (CTAS) scores between
exes [15].
To conduct our analysis of ER visits or hospitalizations follow-
ng immunization, we utilized the self-controlled case series (SCCS)
esign in which individual study subjects serve as their own con-
rol. In the SCCS design, the analysis only includes individuals
ho were both vaccinated and had an event of interest during
he observation period. The rate of endpoints per day is compared
etween an ‘at risk’ period and a control period, which is far enough
emoved from the time of vaccination that it is unlikely for a vac-
ine to have caused the endpoint [16]. For each individual, the
ndex date for the exposure is the date of vaccination. Follow-up
ime for each individual is divided into three distinct intervals: an
xposed period (or ‘at risk’ period), an unexposed period (or control
eriod), and a washout period in between the exposed and unex-
osed periods. Our selection of the ‘at-risk’ and control periods was
ased on our previous study of ER visits and/or hospitalizations
ollowing 2-, 4-, 6-, and 12-month immunizations [9,10]. For the
-, 4- and 6-month immunizations, the ‘at-risk’ period was 0 to 2 (2014) 1153–1159
days following vaccination and the control period was 9 to 18 days
post-vaccination. For the 12-month vaccination, the ‘at-risk’ period
was 4 to 12 days post-vaccination and the control period was  20
to 28 days post-vaccination. We  calculated the relative incidence
of the composite endpoint (ER visits and/or hospital admissions)
in the exposed period versus the unexposed period using a ﬁxed
effects conditional Poisson regression model. The regression model
controlled for exposure period and individual patients, thereby
allowing each individual to serve as his/her own  control. To control
for the dependence of multiple events occurring close together in
time (e.g. an ER visit leading to an admission, or serial ER visits),
each individual was  classiﬁed as having ‘one or more events’ or ‘no
events’ in each of the ‘at-risk’ and control periods.
In order to determine whether the relative incidence of the com-
posite endpoint varied between males and females, we included a
risk by sex interaction term in the SCCS conditional Poisson model.
A likelihood ratio test is used to compare the full model including
the interaction term to the reduced model without the interaction
term in order to test whether the interaction term is statistically sig-
niﬁcant [16]. The parameter estimate of this interaction term can
be exponentiated to yield a “relative incidence ratio” (RIR) which
is equivalent to the ratio of relative incidence in females to the rel-
ative incidence in males: an intuitive measure of the magnitude of
the difference in relative incidences for females versus males. This
RIR has the added beneﬁt of allowing us to overcome the impact of
the healthy vaccinee effect, the decision by parents and health care
providers to forgo vaccination when a child is acutely ill resulting
in the administration of vaccines to children who are in a com-
paratively healthy state [7,8]. Such an effect results in a marked
reduction in events prior to vaccination and can blunt the observa-
tion of an effect in the immediate post-vaccination period. However
the bias due to the healthy vaccinee effect is largely cancelled out
by taking the ratio of relative incidence in two  subgroups (M and
F) where the healthy vaccinee effect manifests similarly.
We calculated excess events per 100,000 vaccinated using the
following approach described in more detail elsewhere [17]:
For one group:
Events per 100, 000 exposures
= 100, 000(
Nexposed/
(
RI − 1/RI
)
× Erisk
) (A)
where Nexposed is the number of vaccinated individuals, RI is the
relative incidence of events in risk versus control periods, and Erisk
is the number of events in the risk period.
To compare excess risk among two groups:
When the excess risk is compared across two groups a common
baseline risk must be assumed. This is achieved by pooling the total
exposures and pooling the total events in the control group and
rearranging the relative incidence expression.
Events per 100, 000 males
= 100, 000(
Nexposed(M+F)/(RIM − 1) × Econtrol(M+F)
) (B)
Events per 100, 000 females
= 100, 000(
Nexposed(M+F)/(RIF − 1) × Econtrol(M+F)
) (C)
where Nexposed (M+F) is the total in both groups who were vaccinated,
RIF and RIM are the sex-speciﬁc relative incidence estimates and
Econtrol (M+F) is the number of events in the control period for males
plus females.
The excess number of events in females compared to males is
simply the difference of the two excess event calculations: (C) – (B).
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.1. Sensitivity analyses
We  conducted several sensitivity analyses to evaluate the
obustness of our conclusions. We  examined the impact of vac-
ination on the incidence of ER visits and admissions separately.
or the 12-month vaccination, we compared the relative incidence
n a pre-vaccination period from −30 to −8 days before vaccina-
ion compared to our original 20–28 days post-vaccination control
eriod. We  also compared the age at the time of receipt of the
2-month vaccination for males and females. We  conducted our
2-month analysis for the period of April 1st 2002 to March 31st
004 (before the introduction of the Men-C vaccine) to evaluate
hether the effect we observed was independent of the addition of
his vaccine to the recommended schedule. Furthermore, we  con-
ucted a restricted analysis which eliminated diagnoses that were
nlikely to be secondary to vaccine reactions.
. Results
Our analysis included data on children born between April 1,
002 and December 31, 2009. For the combined analysis of 2-,
- and 6-month vaccinations, data were available for 1866,136
accinations in 703,156 unique children. For our analysis of the
2-month vaccination, data was available for 548,422 vaccinated
hildren.
For vaccinations at 2, 4 and 6 months combined, the relative
ncidence of events (95% CI) in the ﬁrst 72 h after vaccination
s compared to the control period was 0.69 (0.67 to 0.71). We
bserved no relationship between the relative incidence of an event
nd sex of the child (p = 0.76). When we considered each vaccina-
ion separately, we observed no statistically signiﬁcant difference
etween males and females at 2, 4 or 6 months (Table 1a–c).
For the 12-month vaccination, the relative incidence of events
95% CI) on days 4 to 12 post-vaccination as compared to the control
eriod was 1.35 (1.31 to 1.38). We  observed a signiﬁcant rela-
ionship between sex and the relative incidence of adverse events
ollowing the 12-month vaccination, with female sex being asso-
iated with a signiﬁcantly higher relative incidence (p = 0.0027).
he relative incidence ratio (95% CI) comparing females to males
as 1.08 (1.03 to 1.14), which translates to 192 excess events per
00,000 females vaccinated compared to the number of events that
ould have occurred in 100,000 males vaccinated, or one additional
vent for every 520 females vaccinated (Table 1d). The vast major-
ty of endpoints we observed were ER visits (∼97%). The mean CTAS
core in both males and females was 3.4, suggesting similar acuity
f presentation. In both males and females, the top 5 most respon-
ible diagnoses for ER visits and/or admissions (based on ICD-10
odes) within the risk period following the 12-month vaccination
ere: otitis media, acute upper respiratory tract infection (URI),
ever, viral infection and non-infective gastroenteritis and colitis.
ig. 1 shows the frequency distribution of occurrence of ER visits
nd admissions in proximity to the 6 month index vaccination and
ig. 2 for the 12 month vaccination.
.1. Sensitivity analyses
In our sensitivity analysis examining ER visits and admissions
ollowing the 12-month vaccination separately, we  found that the
ast majority of endpoints we observed were ER visits (∼97%). The
esults for ER visits alone were nearly identical to those obtained
or ER visits and admissions together. The overall patterns were
imilar but attenuated for admissions alone.In another sensitivity analysis using a pre-vaccination control
eriod of −30 to −8 days before the 12-month vaccination, we  still
bserved a signiﬁcant though diminished RIR for girls vs boys (RIR
95% CI) = 1.05 (1.00 to 1.09), p = 0.048. (2014) 1153–1159 1155
To exclude the possibility that time of receipt of the 12-month
vaccination had a role in explaining our ﬁndings, we  compared
the distribution of age at receipt of the 12-month vaccine in males
versus females. The mean age at 12-month vaccination was  381.45
days in females and 381.42 in males. The median age was  376 days,
10th percentile of age was  367 days and 90th percentile was 405
days in both males and females.
In our 12-month analysis for the period before the introduction
of the Men-C vaccine, we  observed a similar RIR for the comparison
between girls and boys, as was  observed in our main analysis over
the whole study period (Table 2).
We performed a restricted event analysis for the 12-month vac-
cination in which we excluded hospital and ER encounters where
the most responsible diagnosis related to endocrine, nutritional
and metabolic diseases, mental and behaviour disorders, injury and
trauma, burns, congenital anomalies and neoplasms. We  observed
a RIR (95% CI) of 1.09 (1.03, 1.15) for females versus males, which
is similar to the result of our non-restricted analysis (Table 3). We
then further restricted the event deﬁnition to include only speciﬁc
types of adverse events that would be expected following MMR
vaccine. The four event types included, based on ICD-10 codes,
were: fever, rash, febrile convulsions and viral enanthema [13,10].
The results of this restricted analysis showed a much larger RIR
for females versus males of 1.23 (95% CI 0.99, 1.51) p = 0.06, which
did not achieve nominal statistical signiﬁcance due to the loss of
events with the restricted event deﬁnition (Table 4). Higher rela-
tive incidences in girls compared to boys were exhibited for each
of the four event types, though none achieved nominal statistical
signiﬁcance.
4. Discussion
We demonstrated that females had an increased risk of ER visits
and/or hospitalizations during a speciﬁed ‘at risk’ period, imme-
diately following the 12-month vaccination but not 2-, 4- and
6-month vaccinations. The increased risk associated with female
sex translates to 192 excess events in females as compared to males,
for every 100,000 infants vaccinated. As previously noted, the vac-
cine routinely administered at 12 months of age in Ontario during
the entire period of study was MMR.  A meningococcal disease (type
C) vaccine was added to Ontario’s publicly-funded immunization
schedule in September 2004. The time period for increase in ER
visits or hospitalizations following 12-month vaccination is con-
sistent with the known risk period following MMR  vaccination
[11,13,18].
Our observations could either be explained by gender differ-
ences – the socially constructed distinction between the sexes, or
by sex differences – the physiological differences between males
and females. If gender differences accounted for our observation,
one explanation would be that parents respond differently to sim-
ilar adverse reactions between boys and girls, and are more likely
to seek medical care for girls. Our analysis cannot ﬁnd evidence to
support or refute this hypothesis, although we may  have expected
lower acuity of presentation in girls if this were the case.
In contrast, it is recognized in the medical literature that impor-
tant physiological differences exist between males and females
that govern their responses to infections and vaccines [19–22]. For
example, estrogen can potentiate antibody responses to antigens,
while both progesterone and androgens tend to have immunoreg-
ulatory or immunosuppressive actions [20,22,23]. Sex differences
in immune responses to measles vaccines have certainly been
observed both in terms of immunogenicity [21,24] and short-term
reactogenicity of both the live-attenuated rubella [1] and both high-
and standard-titer measles vaccines [4,25,26]. The sex-speciﬁc
reactogenicity of rubella vaccine (mostly arthralgias) appears to
1156
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Table 1
(a) ER visits and/or hospitalizations following 2-month vaccinations (diphtheria, pertussis, tetanus, polio, haemophilus inﬂuenzae type b (Hib) and pneumococcus), overall and by sex.
Sex Vaccinated children Events during risk period
(days 0–2)
Events during control
period (days 9–18)
Relative incidence of events
(95% CI)
Relative incidence ratio
(95% CI)
Relative incidence ratio
p-value
Overall 645,109 2315 8826 0.79 (0.75–0.82)
Male  328,742 1270 4870 0.78 (0.74–0.83) Ref. [1]
Female 316,367 1045 3956 0.79 (0.74–0.85) 1.01 (0.92–1.11) 0.7843
(b)  ER visits and/or hospitalizations following 4-month vaccinations (diphtheria, pertussis, tetanus, polio, haemophilus inﬂuenzae type b (Hib) and pneumococcus), overall and by sex.
Sex Vaccinated children Events during risk period
(days 0–2)
Events during control
period (days 9–18)
Relative incidence of Events
(95% CI)
Relative incidence ratio
(95% CI)
Relative incidence ratio
p-value
Overall 622,631 1796 8000 0.67 (0.64–0.71)
Male  317,125 996 4429 0.67 (0.63–0.72)
Female 305,506 800 3571 0.67 (0.62–0.73) 1.00 (0.90–1.10) 0.9422
(c)  ER visits and/or hospitalizations following 6-month vaccinations (diphtheria, pertussis, tetanus, polio, haemophilus inﬂuenzae type b (Hib) and pneumococcus), overall and by sex.
Sex Vaccinated children Events during risk period
(days 0–2)
Events during control
period (days 9–18)
Relative incidence of events
(95% CI)
Relative incidence ratio
(95% CI)
Relative incidence ratio
p-value
Overall 598,396 1741 8795 0.59 (0.56–0.63)
Male  304,147 933 4803 0.58 (0.54–0.63)
Female 294,249 808 3992 0.61 (0.56–0.65) 1.04 (0.94–1.16) 0.4347
(d)  ER visits and/or hospitalizations following 12-month vaccinations (MMR  and Men-C), overall and by sex.
Sex Vaccinated children Events during risk period
(days 4–12)
Events during control
period (days 20–28)
Relative incidence of events
(95% CI)
Relative incidence ratio
(95% CI)
Relative incidence ratio
p-value
Overall 548,422 12,996 9650 1.35 (1.31–1.38)
Male  278,276 6871 5296 1.30 (1.25–1.34)
Female 270,146 6125 4354 1.41 (1.35–1.46) 1.08 (1.03–1.14) 0.0027
K. Wilson et al. / Vaccine 32 (2014) 1153–1159 1157
Fig. 1. Frequency distribution of ER visits and admissions in proximity to the 6-month vaccination (diphtheria, pertussis, tetanus, polio, haemophilus inﬂuenzae type b (Hib)
and  pneumococcus), by sex.
Fig. 2. Frequency distribution of ER visits and admissions in proximity to the 12-month vaccination (MMR  and Men-C), by sex.
1158 K. Wilson et al. / Vaccine 32 (2014) 1153–1159
Table 2
ER visits and/or hospitalizations following 12-month vaccinations (MMR only (2002–2004), overall and by sex.
Sex Vaccinated
children
Events during risk period
(days 4–12)
Events during control
period (days 20–28)
Relative incidence
of events (95% CI)
Relative incidence
ratio (95% CI)
Relative incidence ratio
p-value
Overall 147,320 3181 2228 1.43 (1.35–1.51)
Male  74,965 1676 1251 1.34 (1.25–1.44)
Female 72,355 1505 977 1.54 (1.42–1.67) 1.15 (1.03–1.28) 0.0139
Table 3
ER visits and/or hospitalizations following 12-month vaccinations (restricted events), overall and by sex.
Sex Vaccinated
children
Events during risk period
(days 4–12)
Events during control
period (days 20–28)
Relative incidence
of events (95% CI)
Relative incidence
ratio (95% CI)
Relative incidence ratio
p-value
Overall 548,422 11,854 8376 1.42 (1.38,1.46)
Male  278,276 6245 4584 1.36 (1.31,1.42) Ref. [1]
Female 270,146 5609 3792 1.47 (1.42,1.54) 1.09 (1.03,1.15) 0.0041
Table 4
ER visits and/or hospitalizations following 12-month vaccinations (restricted event types: fever, febrile convulsions, rash, viral enanthema), overall and by sex.
Sex Vaccinated
children
Events during risk period
(days 4–12)
Events during control
period (days 20–28)
Relative incidence
of events (95% CI)
Relative incidence
ratio (95% CI)
Relative incidence ratio
p-value
Overall 548,422 1077 502 2.15 (1.93–2.39)
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Female 270,146 548 230 
e limited to young women post-menarche; obviously not the
opulation targeted in the current study. Several studies of short-
erm reactogenicity after standard titer measles vaccine have found
ncreased rates of reactions in girls, primarily characterized by fever
nd rash, which are manifestations of the cellular immune response
25,26]. In our study, the primary reasons for ER presentation in
irls were acute URIs (13.4%) otitis media (13.3%) and fever (12.1%),
ith rashes being the 6th most common diagnosis, occurring in
.7% of the ER visits in girls. Previous studies have also demon-
trated an increased long-term and serious adverse event rate in
irls following high titer measles vaccination as compared to boys
2–6] although not all studies observed this sex difference [27]. For
xample, Aaby et al. demonstrated that girls who received a high
iter vaccine, which was formerly used in the developing world,
ad a signiﬁcantly higher mortality rate compared to those who
eceived inactivated poliovirus vaccine [5]. No signiﬁcant differ-
nce in mortality rate was observed in boys. The reason for this
ex-speciﬁc effect remains unclear although one study attributed
he risk to DPT and IPV vaccines being administered after the high-
iter measles vaccine [28]. The observation contributed to the rec-
mmendation that the high titer vaccine should be withdrawn [29].
It has been hypothesized that the short-term adverse event rate
ollowing measles vaccination may  be associated with lower mater-
al antibody levels [24,30] and girls have been observed to lose
aternal measles anti-bodies more rapidly than boys [30]. A pos-
ible link with vitamin A has also been identiﬁed with one study
eporting greater reductions in vitamin A levels in girls who receive
he measles vaccine compared to boys [31]. Vitamin A deﬁciency is
ssociated with increased morbidity and mortality from measles,
nd the MMR  vaccine produces a mild measles reaction which may
e more severe in the presence of vitamin A deﬁciency. However,
here is no data to suggest that 12 month-old girls in Ontario have
ower vitamin A levels than their male peers. Our ﬁndings could also
e explained by the relatively lower body weight of girls compared
o boys at the time of vaccination and consequently, the receipt of
 comparatively higher dose of vaccine after adjusting for weight
32]. Another possible explanation lies in the observation that girls
espond differently to the measles virus in general [19,33]. Given
hat the measles vaccine works by creating a mild measles-like
llness, the differential response to this illness between boys and
irls might be expected.1.94 (1.68–2.25)
2.38 (2.04–2.78) 1.23 (0.99–1.51) 0.0610
While we  observed a differential sex response to the 12-month
vaccine, we  did not observe the same effect following 2-, 4- and
6-month vaccinations. This could be a consequence of the overall
lower rate of events with the latter vaccines or could represent the
difference between live and non-living vaccines [34].
Our study has important strengths. As far as we are aware, this
is the largest study examining sex as a predictor of health services
utilization following immunization. The use of the SCCS study
design permitted us to adjust for ﬁxed confounders. The use of
relative incidence ratios to compare relative incidences of events
between sexes allows us to adjust for temporal confounding such
as the healthy vaccinee effect [8]. Our study also has limitations,
which include the use of general vaccination codes. While we  can-
not be certain that the vaccinations administered at 2, 4, 6 and 12
months of age are those recommended in Ontario’s Immunization
Schedule, it would be highly unlikely that they represented other
vaccinations. In our analysis we  assume that the risk and control
periods are consistent between males and females. While it is
possible these may  differ this is not evident in a visual inspection
of the data. A limitation of all SCCS analyses is the possibility
of coincident temporal exposures. A possible example in this
case could be day care exposure which theoretically could affect
the sexes differently with respect to health services utilization.
Finally, the main diagnoses associated with ER visits and hospital
admissions were not validated.
5. Conclusion
We  observed that the relative incidence of ER visits and/or
hospitalizations following the 12-month immunization during an
at-risk period as compared to a control period was higher for
females than for males. Our ﬁndings are hypothesis generating
but raise the possibility that sex differences in short-term reacto-
genicity following routine MMR  vaccination at 12 months may  give
insight into the far more severe sequelae of high titer measles vac-
cination. Given the importance of the measles vaccine to protect
against natural infection, the observation that these events were
mild and the fact that increased reactogenicity in the girls may  indi-
cate less maternal protection, our ﬁndings support current measles
vaccination programs. We  also believe our ﬁndings point to a need
for further studies to investigate pathophysiological reasons for the
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